Corinaldesi R, Galassi A, Borghi C, Pasquali R, Miglioli M, Sacco T, Barbara L
Hepatogastroenterology. 1981 Dec;28(6):319-21.
Clinical efficacy and safety of oxmetidine (400 mg b.i.d.), a new potent specific H2-receptor antagonist, and cimetidine (1 g/day) were compared in a double-blind randomized trial of 4 weeks duration that involved 39 outpatients with endoscopically proven active duodenal ulcer. The disappearance of the ulcer crater leading to complete reepithelization of the bulbs or to the presence of erosions occurred in 17 out of 19 (89.6%) patients treated with oxmetidine, and in 13 out of 20 (65.0%) patients treated with cimetidine (n.s.). Ulcer symptoms and antacid consumption were not different in two groups. No side effects or significant haematological or biochemical abnormalities were found. Both drugs failed to evoke significant changes in the basal levels of prolactin (PRL) and gonadotropins. The higher, though not significant, percentage of healing obtained with oxmetidine had no clinical relevance and needs to be demonstrated in a larger number of patients.
在一项为期4周的双盲随机试验中，对39例经内镜证实为活动性十二指肠溃疡的门诊患者，比较了新型强效特异性H2受体拮抗剂奥美替丁（400毫克，每日两次）和西咪替丁（1克/天）的临床疗效及安全性。接受奥美替丁治疗的19例患者中有17例（89.6%）溃疡灶消失，球部完全重新上皮化或出现糜烂，接受西咪替丁治疗的20例患者中有13例（65.0%）出现上述情况（无统计学差异）。两组的溃疡症状和抗酸剂消耗量无差异。未发现副作用或明显的血液学或生化异常。两种药物均未引起催乳素（PRL）和促性腺激素基础水平的显著变化。奥美替丁获得的愈合率较高（虽无统计学意义），但无临床相关性，需要在更多患者中得到证实。
